Skip to Main Content

Paper Details

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.
bioRxiv
1
2023
AKT, AXL, BRAF, BRAFi, BRAFi/, Dasatinib, HSP70, MAPK, MAPKi, MEK, MEKi, Melanomas, PDX, PI3K, R-PDX, R-PDXs, RTK, YAP, cancer, dasatinib, gene, mTOR, melanoma, patient, patient-derived xenograft models, patients
Author NameAffiliation
Andrew V KossenkovThe Wistar Institute
Katherine L NathansonUniversity of Pennsylvania
Michael A DaviesM.D. Anderson Cancer Center
Michael A DaviesM.D. Anderson Cancer Center
Meenhard HerlynThe Wistar Institute
  • 1 - 5

Datasets

Release 1.2